Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Order Your Report Now For A Swift Delivery: Who Are the Leading Companies in the Kadcyla Market? F. Hoffmann-La Roche Ltd. stands out as a major industry participant, significantly influencing ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 8, 2025 /EINPresswire.com/ -- What is the Expected Compound Annual Growth Rate (CAGR) for the Kadcyla Market in Recent ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

CRVM is outside Roche and Genentech's historical core focus, which has predominately been in oncology with major drugs like Avastin and Herceptin and, more recently, in rare disease and the ...

The study by Ma et al. provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A ...

The most successful clinical trials to date in this disease setting have been conducted with antibody–drug conjugates, leading to the approval of trastuzumab deruxtecan by the US Food and Drug ...

Roivant, the source of Roche’s TL1A prospect, reported a 21% delta compared to placebo after 12 weeks. Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic ...